Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the future of the 340B program, which requires pharmaceutical companies to provide outpatient drugs to eligible health care organizations significantly reduced prices. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Do you foresee any changes in the 340B program?
